CATALYM CTL-002-001 A PHASE 1/2, FIRST-IN-HUMAN, TWO-PART, OPEN-LABEL CLINICAL TRIAL OF INTRAVENOUS ADMINISTRATION OF CTL-002 GIVEN AS MONOTHERAPY AND/OR IN COMBINATION WITH AN ANTI-PD-1 CHECKPOINT INHIBITOR IN SUBJECTS WITH ADVANCED-STAGE, RELAPSED/REFRACTORY SOLID TUMORS - Project - Authors - KSSG Research Database

Project

CATALYM CTL-002-001 A PHASE 1/2, FIRST-IN-HUMAN, TWO-PART, OPEN-LABEL CLINICAL TRIAL OF INTRAVENOUS ADMINISTRATION OF CTL-002 GIVEN AS MONOTHERAPY AND/OR IN COMBINATION WITH AN ANTI-PD-1 CHECKPOINT INHIBITOR IN SUBJECTS WITH ADVANCED-STAGE, RELAPSED/REFRACTORY SOLID TUMORS

Completed - recruitment active · 2022 until 2030

Jörger Markus, Bürki Ramona, Quinter Janine

Jörger, Markus

chief of service
Medizinische Onkologie und Hämatologie · Dept. I

Bürki, Ramona

study nurse
Medizinische Onkologie und Hämatologie · Dept. I

Quinter, Janine

Medizinische Onkologie und Hämatologie · Dept. I